Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery
Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery
Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Actor portrayals.
OPDIVO + chemotherapy and OPDIVO alone is not approved for people younger than 18 years of age.
This pre-surgery and post-surgery immunotherapy treatment may offer you an additional way to treat your condition. Before surgery, these treatments help shrink tumors. After surgery, they attack cancer cells that may remain “hidden” or hard to see and aim to keep them from coming back.
In a clinical trial of 461 people with early-stage NSCLC who were able to have surgery, 229 people were given OPDIVO + chemotherapy before surgery followed by OPDIVO alone after surgery, and 232 people were given platinum-based chemotherapy before surgery followed by placebo after surgery.
Ask your doctor if this OPDIVO-based treatment is right for you.
OPDIVO + chemotherapy and OPDIVO alone will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults with early-stage non-small cell lung cancer (NSCLC) before and after surgery
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.